Interleukin-6 Stimulates Circulating Blood-Derived Endothelial Progenitor Cell Angiogenesis <i>in vitro</i>

Yongfeng Fan(University of California, San Francisco), Jianqin Ye(University of California, San Francisco), Fanxia Shen(University of California, San Francisco), Yiqian Zhu(University of California, San Francisco), Yerem Yeghiazarians(University of California, San Francisco), Wei Zhu(University of California, San Francisco), Yongmei Chen(University of California, San Francisco), Michael T. Lawton(University of California, San Francisco), William L. Young(University of California, San Francisco), Guo‐Yuan Yang(University of California, San Francisco)
Journal of Cerebral Blood Flow & Metabolism
May 16, 2007
Cited by 215Open Access
Full Text

Abstract

Circulating blood endothelial progenitor cells (EPCs) contribute to postnatal vasculogenesis, providing a novel therapeutic target for vascular diseases. However, the molecular mechanism of EPC-induced vasculogenesis is unknown. Interleukin-6 plays multiple functions in angiogenesis and vascular remodeling. Our previous study demonstrated that the polymorphism (174G>C) in IL-6 gene promoter was associated with brain vascular disease. In this study, we investigated if IL-6 receptor is expressed in human EPCs derived from circulating mononuclear cells, and if interleukin-6 (IL-6) stimulates EPC angiogenesis in vitro. First, we isolated and cultured mononuclear cells from adult human circulating blood. We obtained EPC clones that were further cultured and expended for the angiogenesis study. We found that the EPCs possessed human mature endothelial cell phenotypes; however, they proliferated much faster than mature endothelial cells (P<0.05). We then found that IL-6 receptor (gp-80) was expressed in the EPCs, and that administration of IL-6 could activate receptor gp80/gp130 signaling pathways including downstream extracellular signal-regulated kinase 1/2 and STAT3 phosphorylation in EPCs. Furthermore, IL-6 stimulated EPC proliferation, migration, and matrigel tube formation in a dose-dependent manner (P<0.05); anti-IL-6 antibodies or IL-6 receptor could abolish these effects (P<0.05). These results suggest that IL-6 plays a crucial role in the biologic behavior of blood-derived EPCs, which may help clarify the mechanism of IL-6 inflammatory-related diseases.


Related Papers

No related papers found

Powered by citation graph analysis